Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Nkuipou Kenfack, Esther ^a,b   Duranton, Flore ^c   Gayrard, Nathalie ^c   Argilés, Àngel ^c,g,h   Lundin, Ulrika ^d   Weinberger, Klaus M ^d,e,f   Dakna, Mohammed ^a   Delles, Christian ⁱ   Mullen, William ⁱ   Husi, Holger ⁱ   Klein, Julie ^a   Koeck, Thomas ^a   Zur̈big, Petra ^a   Mischak, Harald ^a,i  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c RD Nephrologie   (France)

^d BIOCRATES LIFE SCIENCES AG   (Austria)

^e Forsyth House   (United Kingdom)

^f UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^g Centre de Dialyse Néphrologie Dialyse St Guilhem   (France)

^h Service de Néphrologie Dialyse Péritonéale et Transplantation   (France)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 EICOSENOIC ACID; ACYLCARNITINE; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BUTENOYLCARNITINE; CADHERIN; CALGRANULIN B; CD99 ANTIGEN; DIHEXOSEDIDEOXYHEXOSE; HEPTADECANOIC ACID; HYDROXYAMINO ACID; HYDROXYKYNURENINE; HYDROXYTETRADECENOYLCARNITINE; ISOVALERYLCARNITINE; N(G),N(G) DIMETHYLARGININE; PHOSPHATIDYLCHOLINE; PIMELYLCARNITINE; PROPENOYLCARNITINE; SPHINGOMYELIN; TAMM HORSFALL GLYCOPROTEIN; TETRADECADIENOYLCARNITINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MASS SPECTROMETRY; PROTEOMICS; UPREGULATION; URINALYSIS; BLOOD; DISEASE COURSE; KIDNEY; METABOLISM; METABOLOMICS; PATHOPHYSIOLOGY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; URINE;

AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; METABOLOMICS; PROGNOSIS; PROTEOMICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84901191182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096955     Document Type: Article

References (60)

1. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S12S226.
2. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, et al. (2009) Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 55: 24238.
3. Allison SJ (2013) Chronic kidney disease: The effect of age on CKD outcomes. Nat Rev Nephrol 9: 3.
4. Silberring J, Ciborowski P (2010) Biomarker discovery and clinical proteomics. Trends Analyt Chem 29: 128.
5. Deininger SO, Ebert MP, Futterer A, Gerhard M, Rocken C (2008) MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J Proteome Res 7: 5230-5236.
6. Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H (2013) Urine as a source for clinical proteome analysis: From discovery to clinical application. Biochim Biophys Acta.
7. Good DM, Zürbig P, Argiles A, Bauer HW, Behrens G, et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437.
8. Zürbig P, Jerums G, Hovind P, MacIsaac R, Mischak H, et al. (2012) Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes 61: 3304-3313.
9. Roscioni SS, de ZD, Hellemons ME, Mischak H, Zurbig P, et al. (2012) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56: 259-267.
10. Goek ON, Prehn C, Sekula P, Romisch-Margl W, Doring A, et al. (2013) Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 28: 2131-2138.
11. Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, et al. (2013) A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24: 1330-1338.
12. Posada-Ayala M, Zubiri I, Martin-Lorenzo M, Sanz-Maroto A, Molero D, et al. (2014) Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int 85: 103-111.
13. Argiles A, Siwy J, Duranton F, Gayrard N, Dakna M, et al. (2013) CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis. PLoS One 8: e62837.
14. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, et al. (2013) Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function. Clin J Am Soc Nephrol.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254. (Pubitemid 46768608)
16. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, et al. (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2: 46ps42.
17. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, et al. (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42: 1027-1036.
18. Mischak H, Vlahou A, Righetti PG, Calvete JJ (2014) Putting value in biomarker research and reporting. J Proteomics 96: A1-A3.
19. Unterwurzacher I, Koal T, Bonn GK, Weinberger KM, Ramsay SL (2008) Rapid sample preparation and simultaneous quantitation of prostaglandins and lipoxygenase derived fatty acid metabolites by liquid chromatography-mass spectrometry from small sample volumes. Clin Chem Lab Med 46: 1589-1597.
20. Eibl G, Bernardo K, Koal T, Ramsay SL, Weinberger KM, et al. (2008) Isotope correction of mass spectrometry profiles. Rapid Commun Mass Spectrom 22: 2248-2252. (Pubitemid 351998633)
21. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, et al. (2009) Identification and validation of urinary biomarkers for differential diagnosis and dvaluation of therapeutic intervention in ANCA associated vasculitis. Mol Cell Proteomics 8: 2296-2307.
22. Mischak H, Vlahou A, Ioannidis JP (2013) Technical aspects and interlaboratory variability in native peptide profiling: The CE-MS experience. Clin Biochem 46: 432-443.
23. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, et al. (2004) Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Communications in Mass Spectrometry 18: 149-156. (Pubitemid 38160349)
24. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, et al. (2009) Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J Proteome Res 8: 268-281.
25. Dakna M, He Z, Yu WC, Mischak H, Kolch W (2009) Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1250-1258.
26. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological) 57: 125-133.
27. Girolami M, Mischak H, Krebs R (2006) Analysis of complex, multidimensional datasets. Drug Discov Today: Technologies 3: 13-19.
28. Yang ZR (2004) Biological applications of support vector machines. Brief Bioinform 5: 328-338.
29. R Development Core Team (2008) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
30. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, et al. (2013) Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function. Clin J Am Soc Nephrol.
31. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, et al. (2010) Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant 25: 1896-1903.
32. Zhou J, Chen Y, Liu Y, Shi S, Wang S, et al. (2013) Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy. PLoS ONE 8: e71023.
33. Neilson EG (2006) Mechanisms of disease: Fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2: 101-108.
34. Boor P, Ostendorf T, Floege J (2010) Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656.
35. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH (2006) Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900.
36. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, et al. (2005) Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68: 2131-2142. (Pubitemid 43117787)
37. Ruster C, Wolf G (2006) Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17: 2985-2991. (Pubitemid 44707758)
38. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, et al. (2004) MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 104: 4260-4268. (Pubitemid 39620181)
39. Boger RH, Zoccali C (2003) ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 4: 23-28. (Pubitemid 38234491)
40. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, et al. (2014) Plasma and urinary amino Acid metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol 9: 37-45.
41. Goek ON, Prehn C, Sekula P, Romisch-Margl W, Doring A, et al. (2013) Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 28: 2131-2138.
42. Shah VO, Townsend RR, Feldman HI, Pappan KL, Kensicki E, et al. (2013) Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 8: 363-370.
43. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, et al. (2013) Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function. Clin J Am Soc Nephrol.
44. Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frolich JC (2000) Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 478: 1-3. (Pubitemid 30462247)
45. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, et al. (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with endstage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600. (Pubitemid 29117641)
46. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, et al. (2006) ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37: 2024-2029. (Pubitemid 44309898)
47. Fouque D, Holt S, Guebre-Egziabher F, Nakamura K, Vianey-Saban C, et al. (2006) Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 16: 125-131.
48. Jin K, Norris K, Vaziri ND (2013) Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant 28: 313-320.
49. Vaziri ND (2009) Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 22: 644-651.
50. Drosatos K, Schulze PC (2013) Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 10: 109-121.
51. Guebre-Egziabher F, Alix PM, Koppe L, Pelletier CC, Kalbacher E, et al. (2013) Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function. Biochimie 95: 1971-1979.
52. Li LO, Klett EL, Coleman RA (2010) Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta 1801: 246-251.
53. Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 1033: 30-41.
54. Schmidt-Sommerfeld E, Penn D, Bieber LL, Kerner J, Rossi TM, et al. (1990) Carnitine ester excretion in pediatric patients receiving parenteral nutrition. Pediatr Res 28: 158-165. (Pubitemid 20227515)
55. Reuter SE, Evans AM (2012) Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 51: 553-572.
56. Wanner C, Forstner-Wanner S, Rossle C, Furst P, Schollmeyer P, et al. (1987) Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation. Kidney Int Suppl 22: S132-S135.
57. Tankiewicz A, Pawlak D, Topczewska-Bruns J, Buczko W (2003) Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv Exp Med Biol 527: 409-414. (Pubitemid 38197669)
58. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, et al. (2013) Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function. Clin J Am Soc Nephrol.
59. Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D (2009) Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagul Fibrinolysis 20: 590-594.
60. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D (2009) The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204: 309-314.